Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Chemotherapy ± Thalidomide in Advanced NSCLC
NCT06276933Phase 4Not yet recruiting
- Sponsor
- Tongji University
- Start
- Feb 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of thalidomide in non-small cell lung cancer (NSCLC), sponsored by Tongji University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06276933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276933.